Zai Lab Limited (HKG:9688)
25.95
-0.05 (-0.19%)
Apr 24, 2025, 4:08 PM HKT
Zai Lab Revenue
In the year 2024, Zai Lab had annual revenue of $398.99M USD with 49.59% growth. Zai Lab had revenue of $109.07M in the quarter ending December 31, 2024, with 65.68% growth.
Revenue
$398.99M
Revenue Growth
+49.59%
P/S Ratio
9.25
Revenue / Employee
$213.48K
Employees
1,869
Market Cap
28.65B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Alibaba Health Information Technology | 31.39B |
Sino Biopharmaceutical | 30.72B |
Zai Lab News
- 3 days ago - Zai Lab gets China's acceptance for label expansion of repotrectinib - Seeking Alpha
- 3 days ago - Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors - Business Wire
- 4 weeks ago - Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting - Business Wire
- 4 weeks ago - Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth - Seeking Alpha
- 5 weeks ago - Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks - Seeking Alpha
- 6 weeks ago - Zai Lab gets China review for Pfizer-partnered cervical cancer therapy - Seeking Alpha
- 6 weeks ago - Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
- 6 weeks ago - Insider Sell: Richard Gaynor Sells 2,500 Shares of Zai Lab Ltd (ZLAB) - GuruFocus